Relationship between mutations of the epidermal growth factor receptor gene and drug-resistance to gefitinib in human lung cancer in vitro

Chinese Journal of Lung Cancer

Volumn 12, Issue 1, 2009, Pages 28-32

  Wei, Wei ^a   Fan, Yu ^a,b   Liu, Hongyu ^a   Wu, Zhihao ^a   Wan, Haisu ^a   Yan, Zhiqin ^a   Xu, Ke ^a   Zhou, Qinghua ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

EGFR genes; Gefitinib; Lung neoplasms; Resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MESSENGER RNA;

ARTICLE; CANCER CELL CULTURE; EXON; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; POINT MUTATION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 60149103630     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.01.004     Document Type: Article

References (28)

1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21(12): 2237-2246.
2. Baselga J. Why the epidermal growth factor receptor? The rational for cancer therapy. Oncologist, 2002, 7 Suppl 4: 2-8.
3. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer, 2004, 91(2): 208-212.
4. Zhou QH, Wu ZH. Toward a "tailored" era for basic research and clinical therapy of lung cancer. Chin J Lung Cancer, 2008, 11(1): 1-3.
5. Kosaka T, Yatabe Y, Endo H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 2004, 64(24): 8919-8923.
6. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 2005, 97(5): 339-346.
7. Lynch TJ, Bell DW, Sordella R, et al. Acrivating murations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004, 350(21): 2129-2139.
8. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304(5676): 1497-1500.
9. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101(36): 13306-13311.
10. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth Iactor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsivenessin Taiwan. Clin Cancer Res, 2004, 10(24): 8195-8203.
11. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer, biological and clinical implications. Cancer Res, 2004, 64(24): 8919-8923.
12. Qin BM, Chen X, Zhu JD, et al. Identification of EGFR kinase domain mutations among lung cancer patient in China: implication for targeted cancer therapy. Cell Res, 2005, 15(3): 212-217.
13. Chou TY, Chiu CH, Li L H, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res, 2005, 11(10): 3750-3757.
14. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res, 2005, 11(6): 2106-2110.
15. Mu XL, Li LY, Zhang XT, et al. Gefitinib-sensitive mutalions of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res, 2005, 11(12): 4289-4294.
16. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 352(8): 786-792.
17. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005, 2(3): e75.
18. Honegger AM, Dull TJ, Felder S, et al. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell, 1987, 51(2): 199-209.
19. Liu VW, Grandis JR. EGFR-mediated cell cycle regulation. Anticancer Res, 2002, 22(1A): 1-11.
20. Zhang P, Wang YZ, Kagan E, et al. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J Biol Chem, 2000, 275(29): 22479-22486.
21. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003, 21(12): 2237-2246.
22. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib and erlitinib. PLoS Med, 2005, 2(1): e17.
23. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor- I receptor signaling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer, 2004, 11(4): 793-814.
24. Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res, 2007, 13(9): 2795-2803.
25. Jones HE, Gee JM, Hutcheson IR, et al. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer, 2006, 13 Suppl 1: S45-51.
26. Uchida A, Hirano S, Kitao H, et al. Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Sci, 2007, 98(3): 357-363.
27. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res, 2007, 13(10): 2890-2896.
28. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science, 2004, 305(5687): 1163-1167.